Y Intercept Hong Kong Ltd Has $844,000 Stake in Dyne Therapeutics, Inc. (NASDAQ:DYN)

Key Points

• Y Intercept Hong Kong Ltd significantly increased its stake in Dyne Therapeutics by purchasing an additional 70,897 shares, resulting in ownership of 80,665 shares and a portfolio value of $844,000.
• Dyne Therapeutics reported a loss of $1.05 per share for the latest quarter, falling short of analysts' estimates, with a projected EPS of -3.44 for the current fiscal year.
• Analysts have expressed positive outlooks for Dyne Therapeutics, with a consensus rating of "Moderate Buy" and an average target price of $40.63 despite fluctuating target estimates from various firms.

Y Intercept Hong Kong Ltd grew its position in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 725.8% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 80,665 shares of the company's stock after acquiring an additional 70,897 shares during the quarter. Y Intercept Hong Kong Ltd owned 0.07% of Dyne Therapeutics worth $844,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in shares of Dyne Therapeutics by 8.3% during the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock worth $173,808,000 after buying an additional 566,146 shares during the period. Geode Capital Management LLC increased its holdings in Dyne Therapeutics by 1.5% during the 4th quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company's stock valued at $44,476,000 after purchasing an additional 27,916 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in Dyne Therapeutics during the 4th quarter valued at $42,408,000. Orbimed Advisors LLC increased its holdings in Dyne Therapeutics by 73.2% during the 4th quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company's stock valued at $28,910,000 after purchasing an additional 518,680 shares in the last quarter. Finally, Norges Bank acquired a new stake in Dyne Therapeutics during the 4th quarter valued at $22,384,000. Institutional investors own 96.68% of the company's stock.

Insider Activity at Dyne Therapeutics

In related news, CEO John Cox acquired 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was acquired at an average cost of $9.11 per share, with a total value of $911,000.00. Following the completion of the purchase, the chief executive officer directly owned 242,179 shares in the company, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 20.77% of the stock is currently owned by company insiders.

Dyne Therapeutics Stock Down 3.1%

Shares of Dyne Therapeutics stock traded down $0.29 during trading on Tuesday, reaching $9.02. 529,663 shares of the company were exchanged, compared to its average volume of 2,549,404. Dyne Therapeutics, Inc. has a twelve month low of $6.36 and a twelve month high of $47.45. The business has a 50-day moving average price of $10.89 and a 200-day moving average price of $11.58. The firm has a market capitalization of $1.03 billion, a price-to-earnings ratio of -2.52 and a beta of 1.08.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last announced its quarterly earnings data on Monday, July 28th. The company reported ($0.97) EPS for the quarter, topping analysts' consensus estimates of ($0.99) by $0.02. On average, equities research analysts forecast that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Analysts Set New Price Targets

DYN has been the subject of a number of recent analyst reports. Sanford C. Bernstein initiated coverage on Dyne Therapeutics in a report on Tuesday, June 24th. They set a "market perform" rating and a $13.00 price target for the company. JPMorgan Chase & Co. dropped their price target on Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a report on Tuesday, July 15th. Evercore ISI reissued an "outperform" rating on shares of Dyne Therapeutics in a research note on Friday, July 11th. Guggenheim restated a "buy" rating and set a $50.00 target price on shares of Dyne Therapeutics in a research report on Wednesday, June 18th. Finally, Oppenheimer initiated coverage on Dyne Therapeutics in a research report on Monday, June 2nd. They set an "outperform" rating and a $34.00 target price for the company. One analyst has rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $39.50.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.